MXPA04005079A - Variantes del dominio c2 del factor viii. - Google Patents

Variantes del dominio c2 del factor viii.

Info

Publication number
MXPA04005079A
MXPA04005079A MXPA04005079A MXPA04005079A MXPA04005079A MX PA04005079 A MXPA04005079 A MX PA04005079A MX PA04005079 A MXPA04005079 A MX PA04005079A MX PA04005079 A MXPA04005079 A MX PA04005079A MX PA04005079 A MXPA04005079 A MX PA04005079A
Authority
MX
Mexico
Prior art keywords
factor viii
domain variants
amino acid
loci
inhibitory antibodies
Prior art date
Application number
MXPA04005079A
Other languages
English (en)
Spanish (es)
Inventor
S Lollar John
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of MXPA04005079A publication Critical patent/MXPA04005079A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MXPA04005079A 2001-11-30 2002-11-27 Variantes del dominio c2 del factor viii. MXPA04005079A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33456901P 2001-11-30 2001-11-30
PCT/US2002/037884 WO2003047507A2 (en) 2001-11-30 2002-11-27 Factor viii c2 domain variants

Publications (1)

Publication Number Publication Date
MXPA04005079A true MXPA04005079A (es) 2004-08-19

Family

ID=23307813

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04005079A MXPA04005079A (es) 2001-11-30 2002-11-27 Variantes del dominio c2 del factor viii.

Country Status (8)

Country Link
US (1) US20040249134A1 (enExample)
EP (1) EP1456235A4 (enExample)
JP (1) JP2005511038A (enExample)
CN (1) CN1630666A (enExample)
AU (1) AU2002364509A1 (enExample)
CA (1) CA2462966A1 (enExample)
MX (1) MXPA04005079A (enExample)
WO (1) WO2003047507A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
US7485291B2 (en) 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
WO2005017149A1 (en) 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US20050123997A1 (en) * 2003-10-30 2005-06-09 Lollar John S. Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
PL1750733T3 (pl) * 2004-05-03 2014-05-30 Univ Emory Sposób podawania świńskiego czynnika krzepnięcia VIII pozbawionego domeny B
MY185597A (en) * 2005-09-20 2021-05-24 Avantor Performance Mat Inc Vegetarian protein a preparation and methods thereof
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
IT1394522B1 (it) 2009-01-09 2012-07-05 Invatec Technology Ct Gmbh Dispositivo medicale con rilascio di farmaco
CA2780763A1 (en) * 2009-11-13 2011-05-19 Puget Sound Blood Center Factor viii b cell epitope variants having reduced immunogenicity
RU2579977C2 (ru) 2009-11-13 2016-04-10 Грифольс Терапьютикс Инк. СОДЕРЖАЩИЕ ФАКТОР ФОН ВИЛЛЕБРАНДА (vWF) ПРЕПАРАТЫ И СПОСОБЫ, НАБОРЫ И ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ
CN104788557A (zh) * 2010-09-15 2015-07-22 诺沃—诺迪斯克有限公司 具有减少的细胞摄取的因子viii变体
BR112013011041B1 (pt) 2010-11-05 2021-05-25 Baxalta GmbH variante de fator viii, método para produzir uma variante de fviii, uso da variante de fator viii, e, composição farmacêutica
EP3107561A4 (en) * 2014-02-19 2017-12-20 Bloodworks Factor viii b cell epitope variants having reduced immunogenicity
EP3114138B1 (en) 2014-03-05 2021-11-17 Pfizer Inc. Improved muteins of clotting factor viii
WO2025164792A1 (ja) * 2024-02-02 2025-08-07 学校法人自治医科大学 高比活性／高分泌発現型の第ｖｉｉｉ因子改変体、高発現型の第ｖｉｉｉ因子コード核酸及びそれらの用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
MX9203440A (es) * 1985-04-12 1992-07-01 Genetics Inst Proteinas procoagulantes novedosas.
US5004803A (en) * 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
US5663060A (en) * 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5888974A (en) * 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
US5364771A (en) * 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5744446A (en) * 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US6376463B1 (en) * 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5859204A (en) * 1992-04-07 1999-01-12 Emory University Modified factor VIII
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
PL206105B1 (pl) * 2000-09-19 2010-07-30 Emory Universityemory University Zmodyfikowany ludzki czynnik VIII oraz sposób modyfikacji ludzkiego czynnika VIII ze zmniejszeniem reaktywności na przeciwciało hamujące i zachowaniem aktywności prokoagulacyjnej

Also Published As

Publication number Publication date
AU2002364509A1 (en) 2003-06-17
CN1630666A (zh) 2005-06-22
JP2005511038A (ja) 2005-04-28
WO2003047507A3 (en) 2003-07-17
WO2003047507A2 (en) 2003-06-12
CA2462966A1 (en) 2003-06-12
US20040249134A1 (en) 2004-12-09
EP1456235A4 (en) 2005-08-17
EP1456235A2 (en) 2004-09-15

Similar Documents

Publication Publication Date Title
NL300808I1 (enExample)
PT1200105E (pt) Factor viii modificado
WO2005046583A3 (en) Modified fviii having reduced immunogenicity through mutagenesis of a2 and c2 epitopes
WO2003047507A3 (en) Factor viii c2 domain variants
IL189629A0 (en) Compositions containing human ctla-4 antibodies
PL374080A1 (en) Processes for the preparation of fibrinogen
NO20025405D0 (no) Modulatorer for TNF-alfa-signalisering
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
SE0200844D0 (sv) Chemical compounds
YU68602A (sh) Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje
SI1532131T1 (sl) Motilidne spojine
TR200200278T2 (tr) Kalsilitik bileşimler
DE602004018162D1 (de) hERG1-KANAL-ÖFFNER ZUR BEHANDLUNG VON HERZARRYTHMIEN
YU22802A (sh) Izonipekotamidi za lečenje poremećaja nastalih posredstvom integrina
ATE320255T1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
ATE265418T1 (de) Neue substituierte 3-phenoxy- und 3- phenylalkyloxy-2-phenyl-propylamine
DE60005526D1 (de) Verwendung von 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine zur behandlung von erkrankungen des magen-darm-traktes
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
FA Abandonment or withdrawal